date,title,source
Oct-25-18,Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results,GlobeNewswire
Nov-01-18,Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates,GlobeNewswire
Nov-05-18,Todays Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Titan Pharmaceuticals,ACCESSWIRE
Nov-08-18,Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting,GlobeNewswire
Nov-09-18,Edited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMT,Thomson Reuters StreetEvents
Nov-14-18,Do Options Traders Know Something About Conatus (CNAT) Stock We Don't?,Zacks
Nov-16-18,When Will Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Become Profitable?,Simply Wall St.
Nov-16-18,"Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals  Discovering Underlying Factors of Influence",GlobeNewswire
Dec-06-18,Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study,Zacks
Dec-06-18,Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint,MarketWatch
Dec-06-18,Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis,ACCESSWIRE
Dec-07-18,"The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut",Benzinga
Dec-12-18,"Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate",Zacks
Dec-13-18,"The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis",Zacks
Dec-28-18,Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan,Zacks
Jan-28-19,"Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials",GlobeNewswire
Jan-29-19,Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?,Zacks
Jan-30-19,Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals,ACCESSWIRE
Feb-12-19,Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis,GlobeNewswire
Feb-13-19,Conatus (CNAT) Completes Enrollment in Phase II NASH Study,Zacks
Feb-25-19,Is Conatus Pharmaceuticals Inc.s (NASDAQ:CNAT) CEO Pay Justified?,Simply Wall St.
Mar-01-19,Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results,GlobeNewswire
